Actively Recruiting

Phase Not Applicable
Age: 22Years - 85Years
All Genders
ID06778447

Randomized, Sham-Controlled, Double-Blind Clinical Trial Evaluating VIA Disc NP for Lumbar Discogenic Pain in Degenerative Disc Disease

Led by VIVEX Biologics, Inc. · Updated on 2026-04-24

496

Participants Needed

19

Research Sites

52 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This research investigates the safety and effectiveness of VIA Disc NP, a non-surgical treatment designed to supplement nucleus pulposus tissue in people experiencing lumbar discogenic pain due to degenerative disc disease (DDD). The study is a randomized, sham-controlled, double-blind trial conducted across multiple centers, including an initial open-label roll-in phase for one participant per site. It focuses on adults aged 22 to 85 years with moderate to severe disc degeneration confirmed by MRI and persistent low-back pain unresponsive to conservative care. Participants receive a single intradiscal injection of VIA Disc NP, which is made from processed cadaveric disc tissue, at up to two affected lumbar levels (L1-S1). Participants who enroll after the roll-in phase are randomly assigned in a 2:1 ratio to receive either the VIA Disc NP injection or a sham procedure where a needle is inserted but no injection is given. Those initially assigned to the sham group who continue to have symptoms after 12 months may cross over to receive VIA Disc NP and undergo an additional 12 months of follow-up. During the study, participants will be monitored through assessments including pain severity using the Visual Analog Scale (VAS) and safety evaluations for any treatment-related adverse events over a 12-month period. The primary outcomes measure the proportion of participants achieving meaningful improvement in pain scores and the incidence of treatment-related side effects. The study duration includes screening, treatment, and follow-up visits, with careful tracking of participants' symptoms and safety throughout the trial.

CONDITIONS

Brief Title

Clinical Trial Evaluating the Safety and Efficacy of Nucleus Pulposus Allograft in Participants With Degenerative Disc Disease

Who Can Participate

Age: 22Years - 85Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 22 to 85 years old
  • Diagnosis of moderate to severe degenerative disc disease confirmed by MRI, Modified Pfirrmann Grade 3-7
  • Chronic axial midline low-back pain for at least 6 months unresponsive to at least 3 months of conservative care
  • Low-back pain severity score between 40 and 90 mm on the Visual Analog Scale
  • Oswestry Disability Index (ODI) score between 40 and 80
  • Positive sustained hip flexion test
  • Demonstrated intolerance to sitting
  • Able and willing to provide written informed consent
  • Willing and able to comply with all study procedures and available for study duration with life expectancy over 2 years
Not Eligible

You will not qualify if you...

  • Contraindications to sedation or anesthetic protocols
  • More than two lumbar discs affected by degeneration (3 or more discs with Modified Pfirrmann grade 3 or higher)
  • Disc height less than 4 mm between L1 and S1
  • Symptomatic vertebral compression fracture
  • Prior lumbar spine surgery
  • Sacroiliac joint fusion within past 6 months
  • Received certain lumbar injections or procedures within 3 months prior to Day 0 procedure
  • Previous intradiscal stem cell or biological therapy at target level within 12 months
  • Evidence of lumbar instability or significant spinal conditions (e.g., grade 2+ spondylolisthesis, spondylitis)
  • Full thickness annular tear or abnormal disc morphology
  • Clinical suspicion of facet joint pain as primary source
  • Unstable systemic diseases or infections
  • Prior VIA Disc NP treatment
  • Substance abuse or opioid use over 90 MME/day
  • Current radiation, chemotherapy, immunosuppression, or chronic steroid therapy above allowed dose
  • Metal or ceramic implants in lumbar spine
  • Contraindications to MRI including incompatible devices
  • Recent litigation related to back pain
  • Unmanaged psychiatric conditions or recent medication changes
  • Traumatic neurological disorders impacting study
  • Pregnant or breastfeeding women or those not using reliable contraception
  • Use of experimental treatments for same condition within 6 months
  • Other persistent nerve or pain conditions like radiculopathy or cauda equina syndrome

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - 12 months

Participants receive a single dose of VIA Disc NP or a sham procedure for lumbar discogenic pain.

Multiple visits during the 12 months for assessments

Trial Site Locations

Total: 19 locations

1

Interventional Pain Management Napa Valley Orthopedic Medical Group

Napa, California, United States, 94558

Actively Recruiting

2

Source Healthcare

Santa Monica, California, United States, 90403

Actively Recruiting

3

Premier Spine and Pain Institute

Thornton, Colorado, United States, 80229

Actively Recruiting

4

The Orthopaedic Institute

Gainesville, Florida, United States, 32607

Actively Recruiting

5

Georgia Pain Management

Woodstock, Georgia, United States, 30189

Actively Recruiting

6

Henry Community Health

New Castle, Indiana, United States, 47362

Actively Recruiting

7

University of Kansas

Kansas City, Kansas, United States, 66160

Actively Recruiting

8

University of Kentucky

Lexington, Kentucky, United States, 40504

Actively Recruiting

9

Ochsner Clinic Foundation

New Orleans, Louisiana, United States, 70115

Actively Recruiting

10

Spine Institute of Louisiana

Shreveport, Louisiana, United States, 71101

Actively Recruiting

11

Paradigm Health System

Slidell, Louisiana, United States, 70458

Actively Recruiting

12

Nevada Advanced Pain Specialists

Reno, Nevada, United States, 89511

Actively Recruiting

13

Premier Pain Centers

Shrewsbury, New Jersey, United States, 07702

Actively Recruiting

14

Northwell Health

New York, New York, United States, 10019

Actively Recruiting

15

Crystal Coast Pain Management

New Bern, North Carolina, United States, 28560

Actively Recruiting

16

Pacific Sports & Spine

Eugene, Oregon, United States, 97404

Actively Recruiting

17

Procura Pain & Spine

Shenandoah, Texas, United States, 77384

Actively Recruiting

18

Precision Spine Care

Tyler, Texas, United States, 75701

Actively Recruiting

19

The Spine and Nerve Center C/O Clinical Research

Charleston, West Virginia, United States, 25301

Actively Recruiting

Loading map...

Research Team

L

Leslie Zaccari

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

CROSSOVER

Primary Purpose

TREATMENT

Number of Arms

2

Similar Trials

Lumbar Operatively Inserted PerQdisc Artificial Implant Foll...

Degenerative Disc Disease

Actively Recruiting

10 locations

A Prospective, Randomized, Double-Blinded, Sham-Controlled, ...

Degenerative Disc Disease

Actively Recruiting

14 locations

Comparison of Clinical Outcomes Following ACDF With Instrume...

Degenerative Disc Disease

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here